Biopolym. Cell. 2011; 27(3):167-180.
Baculovirus vectors in experimental gene- and vaccine therapy
1Solomko A. P., 1Zaharuk O. A., 1Chaschina L. I., 1Strokovskaya L. I.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680


The article provides a brief overview of the literature on target design, exploration properties and effectiveness of the application of recombinant baculoviruses in model systems in vivo. The results of experiments with wild and recombinant baculoviruses are analysed in regard to the priority areas of biomedicine such as tissue regeneration, gene therapy of cancer, development of vaccines against infectious diseases and malignancies
Keywords: baculovirus, genevector, immunovector, mammals, system in vivo


[1] Zhang X., Godbey W. T. Viral vectors for gene delivery in tissue engineering Adv. Drug Deliv. Rev 2006 58, N 4 P. 515– 534.
[2] Guo Z. S., Thorne S. H., Bartlett D. L. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cellmediated delivery of oncolytic viruses Biochim. Biophys. Acta 2008 1785, N 2 P. 217–231.
[3] Nayak S., Herzog R. W. Progress and prospects: immune responses to viral vectors Gene Ther 2010 17, N 3 P. 295–304.
[4] Hu Y. C. Baculoviral vectors for gene delivery: a review Curr. Gene. Ther 2008 8, N 1 P. 54–65.
[5] Solomko A. P., Zaharuk O. A., Chashchina L. I., Strokovskaya L. I. Baculovirus integration with the vertebrate cells in system in vitro Biopolym. Cell 2010 26, N 6 P. 441–449.
[6] Luckow V. A., Summers M. D. Signals important for high-level expression of foreign genes in Autographa californica nuclear polyhedrosis virus expression vectors Virology 1988 167, N 1 P. 56–71.
[7] Kim Y. K., Jiang H. L., Je Y. H., Cho M. H., Cho C. S. Modification of baculovirus for gene therapy Commun. Curr. Res. Edu. Topics and Trends Appl. Microbiol. / Ed. A. Mendez-Vilas Badajoz, 2007 Vol. 2 P. 875–884.
[8] Vacanti J. P., Langer R. Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation Lancet 1999 354, Suppl 1 P. S32– S34.
[9] Reddi A. H. Morphogenesis and tissue engineering of bone and cartilage: inductive signals, stem cells, and biomimetic biomaterials Tissue Eng 2000 6, N 4 P. 351–359.
[10] Nakashima M., Reddi A. H. The application of bone morphogenetic proteins to dental tissue engineering Nat. Biotechnol 2003 21, N 9 P. 1025–1032.
[11] Peterson B., Zhang J., Iglesias R., Kabo M., Hedrick M., Benhaim P., Lieberman J. R. Healing of critically sized femoral defects, using genetically modified mesenchymal stem cells from human adipose tissue Tissue Eng 2005 11, N 1–2 P. 120–129.
[12] Ho Y. C., Chen H. C., Wang K. C., Hu Y. C. Highly efficient baculovirus-mediated gene transfer into rat chondrocytes Biotechnol. Bioeng 2004 88, N 5 P. 643–651.
[13] Sung L. Y., Lo W. H., Chiu H. Y., Chen H. C., Chung C. K., Lee H. P., Hu Y. C. Modulation of chondrocyte phenotype via baculovirus-mediated growth factor expression Biomaterials 2007 28, N 23 P. 3437–3447.
[14] Sung L. Y., Chiu H. Y., Chen H. C., Chen Y. L., Chuang C. K., Hu Y. C. Baculovirus-mediated growth factor expression in dedifferentiated chondrocytes accelerates redifferentiation: effects of combinational transduction Tissue Eng., Part A 2009 15, N 6 P. 1353–1362.
[15] Lee H. P., Matsuura Y., Chen H. C., Chen Y. L., Chuang C. K., Abe T., Hwang S. M., Shiah H. C., Hu Y. C. Baculovirus transduction of chondrocytes elicits interferon-alpha/beta and suppresses transgene expression J. Gene Med 2009 11, N 4 P. 302–312.
[16] Chen H. C., Chang Y. H., Chuang C. K., Lin C. Y., Sung L. Y., Wang Y. H., Hu Y. C. The repair of osteochondral defects using baculovirus-mediated gene transfer with de-differentiated chondrocytes in bioreactor culture Biomaterials 2009 30, N 4 P. 674–681.
[17] Kumar S., Chanda D., Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells Gene Ther 2008 15, N 10 P. 711–715.
[18] Ho Y. C., Lee H. P., Hwang S. M., Lo W. H., Chen H. C., Chung C. K., Hu Y. C. Baculovirus transduction of human mesenchymal stem cell-derived progenitor cells: variation of transgene expression with cellular differentiation states Gene Ther 2006 13, N 20 P. 1471–1479.
[19] Chuang C. K., Sung L. Y., Hwang S. M., Lo W. H., Chen H. C., Hu Y. C. Baculovirus as new gene delivery vector for stem cell engineering and bone tissue engineering Gene Ther 2007 14, N 19 P. 1417–1424.
[20] Chuang C. K., Wong T. H., Hwang S. M., Chang Y. H., Chen G. Y., Chiu Y. C., Huang S. F., Hu Y. C. Baculovirus transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantation Mol. Ther 2009 17, N 5 P. 889–896.
[21] Lin C. Y., Chang Y. H., Lin K. J., Yen T. C., Tai C. L., Chen C. Y., Lo W. H., Hsiao I. T., Yu Y. C. The healing of critical-sized femoral segmental bone defects in rabbits using baculovirus-engineered mesenchymal stem cells Biomaterials 2010 31, N 12 P. 3222–3230.
[22] Lo W. H., Hwang S. M., Chuang C. K., Chen C. Y., Hu Y. C. Development of a hybrid baculoviral vector for sustained transgene expression Mol. Ther 2009 17, N 4 P. 658–666.
[23] Chen C. Y., Wu H. H., Chen C. P., Chern S. R., Hwang S. M., Huang S. F., Lo W. H., Chen G. Y., Hu Y. C. Biosafety assessment of human mesenchymal stem cells engineered by hybrid baculovirus vectors. Mol Pharm. 2011;8(5):1505-14.
[24] Wardley R. C., Berlinski P. J., Thomsen D. R., Meyer A. L., Post L. E. The use of feline herpesvirus and baculovirus as vaccine vectors for the gag and env genes of feline leukaemia virus J. Gen. Virol 1992 73, pt 7 P. 1811–1818.
[25] Gronowski A. M., Hilbert D. M., Sheehan K. C., Garotta G., Schreiber R. D. Baculovirus stimulates antiviral effects in mammalian cells J. Virol 1999 73, N 12 P. 9944–9951.
[26] Aoki H., Sakoda Y., Jukuroki K., Takada A., Kida H., Fukusho A. Induction of antibodies in mice by a recombinant baculovirus expressing pseudorabies virus glycoprotein B in mammalian cells Vet. Microbiol 1999 68, N 3–4 P. 197–207.
[27] Abe T., Takahashi H., Hamazaki H., Miyano-Kurosaki N., Matsuura Y., Takaku H. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice J. Immunol 2003 171, N 3 P. 1133–1139.
[28] Facciabene A., Aurisicchio L., La Monica N. Baculovirus vectors elicit antigen-specific immune responses in mice J. Virol 2004 78, N 16 P. 8663–8672.
[29] Li Y., Ye J., Cao S., Xiao S., Zhao Q., Liu X., Jin M., Chen H. Immunization with pseudotype baculovirus expressing envelope protein of Japanese encephalitis virus elicits protective immunity in mice J. Gene Med 2009 11, N 1 P. 57–65.
[30] Lu L., Yu L., Kwang J. Baculovirus surface-displayed hemagglutinin of H5N1 influenza virus sustains its authentic cleavage, hemagglutination activity, and antigenicity Biochem. Biophys. Res. Commun 2007 358, N 2 P. 404–409.
[31] Wu Q., Fang L., Wu X., Li B., Luo R., Ju Z., Jin M., Chen H., Xiao S. A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens Mol. Immunol 2009 46, N 11–12 P. 2210–2217.
[32] Prabakaran M., Madhan S., Prabhu N., Qiang J., Kwang J. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection J. Virol 2010 84, N 7 P. 3201–3209.
[33] Prabakaran M., He F., Meng T., Madhan S., Yunrui T., Jia Q., Kwang J. Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages J. Virol 2010 84, N 22 P.11822–11830.
[34] Jin R., Lv Z., Chen Q., Quan Y., Zhang H., Li S., Chen G., Zheng Q., Jin L., Wu X., Chen J., Zhang Y. Safety and immunogenicity of H5N1 influenza vaccine based on baculovirus surface display system of Bombyx mori PLoS One 2008 3, N 12 e3933.
[35] Beck N. B., Sidhu J. S., Omiecinski C. J. Baculovirus vectors repress phenobarbital-mediated gene induction and stimulate cytokine expression in primary cultures of rat hepatocytes Gene Ther 2000 7, N 15 P. 1274–1283.
[36] Hashimoto K., Suzuki T., Sakai R., Miyazawa Y., Saito R., Yamamoto H., Nakayama T., Miyano-Kurosaki N., Takaku H. Innate immunity activation in mouse dendritic cells infected by baculovirus J. Immunol 2007 178, suppl:B188.
[37] Hervas-Stubbs S., Rueda P., Lopez L., Leclerc C. Insect baculovirues strongly potentiate adaptive immune responses by inducing type I IFN J. Immunol 2007 178, N 4 P. 2361–2369.
[38] Abe T., Hemmi H., Miyamoto H., Moriishi K., Tamura S., Takaku H., Akira S., Matsuura Y. Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus J. Virol 2005 79, N 5 P. 2847–2858.
[39] Abe T., Kaname Y., Wen X., Tani H., Moriishi K., Uematsu S., Takeuchi O., Ishii K.J., Kawai T., Akira S., Matsuura Y. Baculovirus induces type I interferon production through Toll-like receptor-dependent and -independent pathways in a cell-typespecific manner J. Virol 2009 83, N 15 P. 7629–7640.
[40] Kenoutis C., Efrose R. C., Swevers L., Lavdas A. A., Gaitanou M., Matsas R., Latrou K. Baculovirus-mediated gene delivery into mammalian cells does not alter their transcriptional and differentiating potential but is accompanied by early viral gene expression J. Virol 2006 80, N 8 P. 4135–4146.
[41] Chen G. Yu., Shiah H. C., Su H. J., Chen C. Yu., Chuang Y. J., Lo W. H., Huang J. L., Chuang C. K., Hwang S. M., Hu Y. C. Baculovirus transduction of mesenchymal stem cells triggers the toll-like receptor 3 pathway J. Virol 2009 83, N 20 P. 10548–10556.
[42] Tani H., Abe T., Matsunaga T. M., Moriishi K., Matsuura Y. Baculovirus vector for gene delivery and vaccine development Fut. Virol 2008 3, N 1 P. 35–43.
[43] Hu Y. C., Yao K., Wu T. Y. Baculovirus as an expression and/or delivery vehicle for vaccine antigens Expert Rev. Vaccines 2008 7, N 3 P. 363–371.
[44] Wilson S., Baird M., Ward V. K. Delivery of vaccine peptides by rapid conjugation to baculovirus particles Vaccine 2008 26, N 20 P. 2451–2456.
[45] Boublik Y., Di Bonito P., Jones I. M. Eukaryotic virus display: engineering the major surface glycoprotein of the Autographa californica nuclear polyhedrosis virus (AcNPV) for the presentation of foreign proteins on the virus surface Biotechnology 1995 13, N 10 P. 1079–1084.
[46] Mottershead D., van der Linden I., von Bonsdorff C. H., Keinanen K., Oker-Blom C. Baculoviral display of the green fluorescent protein and rubella virus envelope proteins Biochem. Biophys. Res. Commun 1997 238, N 3 P. 717–722.
[47] Makela A. R., Oker-Blom C. Baculovirus display: a multifunctional technology for gene delivery and eukaryotic library development Adv. Virus Res 2006 68 P. 91–112.
[48] Yoshida S., Kondoh D., Arai E., Matsuoka H., Seki C., Tanaka T., Okada M., Ishii A. Baculovirus virions displaying Plasmodium berghei circumsporozoite protein protect mice against malaria sporozoite infection Virology 2003 316, N 1 P. 161– 170.
[49] Yoshida S., Kawasaki M., Hariguchi N., Hirota K., Matsumoto M. A Baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice Infect. Immun 2009 77, N 5 P. 1782–1789.
[50] Yoshida S., Araki H., Yokomine T. Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice Infect. Immun 2010 78, N 2 P. 595–602.
[51] Strauss R., Huser A., Ni S., Tuve S., Kiviat N., Sow P. S., Hofmann C., Lieber A. Baculovirus-based vaccination vectors allow for efficient induction of immune responses against Plasmodium falciparum circumsporozoite protein Mol. Ther 2007 15, N 1 P. 193–202.
[52] Bruna-Romero O., Rocha C. D., Tsuji M., Gazzinelli R. T. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif Vaccine 2004 22, N 27–28 P. 3575–3584.
[53] Schutz A., Scheller N., Breinig N., Meyerhans A. The Autographa californica nuclear polyhedrosis virus AcNPV induces functional maturation of human monocyte-derived dendritic cells Vaccine 2006 24, N 49–50 P. 7190–7196.
[54] Suzuki T., Chang M. O., Kitajima M., Takaku H. Baculovirus activates murine dendritic cells and induces non-specific NK cell and T cell immune responses Cell Immunol 2010 262, N 1 P. 35–43.
[55] Wang C. Y., Li F., Yang Y., Guo H. Y., Wu C. X., Wang S. Recombinant baculovirus containing the diphtheria toxin A gene for malignant glioma therapy Cancer Res 2006 66, N 11 P. 5798–5806.
[56] Kim C. H., Yoon J. S., Sohn H. J., Kim C. K., Paik S. Y., Hong Y. K., Kim T. G. Direct vaccination with pseudotype baculovirus expressing murine telomerase induces anti-tumor immunity comparable with RNA-electroporated dendritic cells in a murine glioma model Cancer Lett 2007 250, N 2 P. 276–283.
[57] Kitajima M., Abe T., Miyano-Kurosaki N., Taniguchi M., Nakayama T., Takaku H. Induction of natural killer cell-dependent antitumor immunity by the Autographa californica multiple nuclear polyhedrosis virus Mol. Ther 2008 16, N 2 P. 261–268.
[58] Kitajima M., Takaku H. Induction of antitumor acqired immunity by baculovirus Autographa californica multiple nuclear polyhedrosis virus infection in mice Clin. Vaccine Immunol 2008 15, N 2 P. 376–378.
[59] Mossoba M. E., Medin J. A. Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials Expert. Rev. Vaccines 2006 5, N 5 P. 717–732.
[60] Suzuki T., Chang M. O., Kitajima M., Takaku H. Induction of antitumor immunity against mouse carcinoma by baculovirusinfected dendritic cells Cell Mol. Immunol 2010 7, N 6 P. 440–446.
[61] Danen-Van Oorschot A. A., Fischer D. F., Grimbergen J. M., Klein B., Zhuang S., Falkenburg J. H., Backendorf C., Quax P. H., Van der Eb A. J., Noteborn M. H. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells Proc. Natl Acad. Sci. USA 1997 94, N 11 P. 5843– 5847.
[62] Pietersen A. M., Rutjes S. A., van Tongeren J., Vogels R., Wesseling J. G., Noteborn M. H. The tumor-selective viral protein apoptin effectively kills human biliary tract cancer cells J. Mol. Med 2004 82, N 1 P. 56–63.
[63] Pietersen A. M., van der Eb M. M., Rademaker H. J., van den Wollenberg D. J., Rabelink M. J., Kuppen P. J., van Dierendonck J. H., van Ormondt H., Masman D., van de Velde C. J., van der Eb A. J., Hoeben R. C., Noteborn M. H. Specific tumorcell killing with adenovirus vectors containing the apoptin gene Gene Ther 1999 6, N 5 P. 882–892.
[64] Pan Y., Fang L., Fan H., Luo R., Zhao Q., Chen H., Xiao S. Antitumor effects of recombinant pseudotype baculovirus expressing Apoptin in vitro and in vivo Int. J. Cancer 2010 126, N 11 P. 2741–2751.
[65] Eberle J., Krasagakis K., Orfanos C. E. Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro Int. J. Cancer 1997 71, N 3 P. 396–401.
[66] Kim Y. K., Kwon J. T., Choi J. Y., Jiang H. L., Arote R., Jere D., Je Y. H., Cho M. H., Cho C. S. Suppression of tumor growth in xenograft model mice by programmed cell death 4 gene delivery using folate-PEG-baculovirus Cancer Gene Ther 2010 17, N 11 P. 751–760.